Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center
Phase: PHASE2
Conditions: Malignant Bowel Obstruction
Sponsor: Roswell Park Cancer Institute

Document Coversheet 
 
 Study Title:   Palliative Management of Inoperable Malignant Bowel Obstruction: A 
Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center 
 
 
Institution/Site:  
Roswell Park Comprehensive Cancer Center 
Document (Approval/Update) Date: 
10/18/2021 
NCT Number: 
NCT04027348 
IRB Number 
I 74018 
 
 

Roswell Park Protocol No.: I 74018
10/18/21
Page 1 of 46
PROTOCOL TITLE:
Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open 
Label, Phase-2 Study at an NCI Comprehensive Cancer Center
PROTOCOL NUMBER: 
I 74018
PRINCIPAL INVESTIGATOR:
Amy A. Case, MD
Roswell Park Comprehensive Cancer Center
Elm and Carlton Street
Buffalo, New York 14263
716-845-8214
Amy.Case@roswellpark.org
VERSION NUMBER: 
Amendment 9
DATE:
10/18/21
Confidentiality Statement
Any and all information presented in this document shall be treated as confidential and shall 
remain the exclusive property of the party (ies) mentioned above (Roswell Park Cancer Institute 
d/b/a Roswell Park Comprehensive Cancer Center). The use of such confidential information 
must be restricted to the recipient for the agreed purpose and must not be disclosed, published, or 
otherwise communicated to any unauthorized persons, for any reason, in any form whatsoever 
without the prior written consent of the party(ies) above.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 2 of 46
Table of Contents
1
Objectives ................................................................................................................................4
1.1
Primary Objective.................................................................................................................4
1.2
Secondary Objectives ...........................................................................................................4
2
Background..............................................................................................................................4
2.1
Malignant Bowel Obstruction...............................................................................................4
2.2
Rationale...............................................................................................................................6
3
Inclusion and Exclusion Criteria .............................................................................................7
3.1
Inclusion Criteria ..................................................................................................................7
3.2
Exclusion Criteria .................................................................................................................7
3.3
Inclusion of Women and Minorities.....................................................................................8
4
Local and Study-Wide Number of Subjects ............................................................................8
5
Local and Study-Wide Recruitment Methods .........................................................................8
6
Multi-Site Research .................................................................................................................8
7
Study Timelines.......................................................................................................................9
8
Study Endpoints.......................................................................................................................9
8.1
Primary Endpoint..................................................................................................................9
8.2
Secondary Endpoints ..........................................................................................................10
9
Design....................................................................................................................................10
10
Treatment...............................................................................................................................12
10.1
Dosing and Administration.................................................................................................12
10.2
Dose Modifications and Management of Adverse Events .................................................13
10.2.4
Allergic reaction to octreotide, dexamethasone, or metoclopramide..............................15
10.3
General Concomitant Medication and Supportive Care.....................................................15
10.4
Duration of Treatment ........................................................................................................16
11
Procedures Involved ..............................................................................................................16
11.1
Participant Registration ......................................................................................................16
11.2
Pre-treatment Screening......................................................................................................16
11.3
Evaluations Performed during Inpatient Treatment ...........................................................17
11.4
Evaluations Performed Prior to Discharge .........................................................................17
11.5
Discharge Follow-up ..........................................................................................................17
11.6
Post-Treatment Follow-Up Evaluations .............................................................................18
11.7
Long Term Follow-Up Evaluations....................................................................................18
12
Withdrawal of Subjects..........................................................................................................18
12.1
Treatment Discontinuation .................................................................................................18
13
Risks to Subjects....................................................................................................................19
13.1
Dexamethasone...................................................................................................................19
13.2
Metoclopramide..................................................................................................................20
13.3
Octreotide ...........................................................................................................................20
14
Potential Benefits to Subjects ................................................................................................20
15
Data and Specimen Banking..................................................................................................20
16
Measurement of Effect ..........................................................................................................20
17
Safety Evaluation...................................................................................................................21
17.1
Adverse Events ...................................................................................................................21
17.2
Grading and Reporting Adverse Events .............................................................................22
17.3
Reporting Adverse Events:.................................................................................................22
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 3 of 46
17.4
Serious Adverse Events ......................................................................................................23
17.5
Follow-Up for Serious Adverse Events..............................................................................23
17.6
Unanticipated Problems......................................................................................................24
18
Data Management and Confidentiality..................................................................................24
18.1
Data Collection ...................................................................................................................24
18.2
Maintenance of Study Documents......................................................................................25
18.3
Revisions to the Protocol....................................................................................................25
18.4
Termination of the Study....................................................................................................25
18.5
Confidentiality ....................................................................................................................25
19
Statistical Plan .......................................................................................................................25
20
Provisions to Monitor the Data to Ensure the Safety of Subjects..........................................27
21
Vulnerable Populations..........................................................................................................27
22
Community-Based Participatory Research............................................................................27
23
Sharing of Results with Subjects ...........................................................................................27
24
Setting....................................................................................................................................27
25
Provisions to Protect the Privacy Interests of Subjects .........................................................27
26
Resources Available ..............................................................................................................28
27
Prior Approvals......................................................................................................................28
28
Compensation for Research-Related Injury...........................................................................28
29
Economic Burden to Subjects................................................................................................28
30
Consent Process.....................................................................................................................28
31
Process to Document Consent in Writing..............................................................................29
32
Drugs or Devices ...................................................................................................................29
33
References..............................................................................................................................30
34
Appendices/ SupplemEnts.....................................................................................................32
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 4 of 46
1
OBJECTIVES
1.1
Primary Objective

To identify role of palliative medical management of inoperable malignant bowel 
obstruction (MBO) with octreotide, dexamethasone and metoclopramide given together as 
triple therapy.
1.2
Secondary Objectives

To examine the time to de-obstruction

To assess how well patients with MBO tolerate the combination therapy regimens

To measure the overall survival of patients who receive the triple therapy at 3 and 6 months 
post obstruction or de-obstruction
2
BACKGROUND
2.1
Malignant Bowel Obstruction
Bowel obstruction is defined as the failure of transit of contents through the intestinal lumen. 
Usually, a diagnosis is made based on clinical suspicion and confirmed radiographically. 
Malignant bowel obstruction as per consensus definition is based on clinical evidence of 
obstruction distal to the ligament of Treitz with presence of primary intra-abdominal malignancy 
or intra-peritoneal tumor with extra-abdominal primary tumor [1]
MBO is a frequent and challenging complication in patients with advanced malignancy especially 
in gynecological and gastrointestinal tract tumors. In general, prevalence of MBO is 5-15% in 
advanced malignancy. Prevalence of MBO is 20-50% in gynecological malignancies and 10-29% 
in colorectal malignancies. The higher overall frequency of MBO in women can be explained by 
the high incidence of this complication in ovarian cancers. Malignancy is responsible for the 
majority of cases but in about one-third of cases, presence of benign causes, such as adhesions 
from a previous bowel surgery, radiation enteritis and hernia have been implicated. MBO can be 
partial or complete. Obstruction could be at one level or multiple levels. Reported incidences of 
small bowel obstruction are higher (66%) than large bowel (33%), and both can occur 
simultaneously (20%). Nausea, abdominal pain, colic, and dry mouth may be present regardless 
of the level of obstruction. Occurrence of MBO is a poor prognostic sign. Besides portending a 
poor prognosis, MBO causes a heavy burden of distressing symptoms to the patient and emotional 
turmoil to the family [2 3].
The pathophysiology of malignant bowel obstruction involves a vicious cycle of distension due to 
gas and non-absorbed secretions, followed by increased fluid secretion, causing more distension 
in the bowel. The bowel mucosa, in turn via an inflammatory response and release of vasoactive 
intestinal peptide, becomes damaged by the hypertensive state of distension and produces even 
more secretions [3]. This cycle results in bloating, pain, cramping, nausea, and vomiting. The 
symptoms vary in severity and rapidity of onset, depending on the level of the obstruction [3]. For 
instance, in gastric outlet obstruction, there is early and severe nausea and vomiting. In small-
bowel obstruction, there is pronounced cramping and nausea with vomiting. In large-bowel 
obstruction, symptoms appear later in the course of the obstruction, with considerable distension 
and occasional paradoxical diarrhea owing to bacterial overgrowth. There can be 2 types of pain—
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 5 of 46
a continuous one, from the distension and the tumor itself, and a cramping one, which can be 
episodic, and which occurs mostly after meals. The vomit might be feculent in large-bowel 
obstruction, whereas it is biliary in small-bowel and gastric outlet obstructions. In complete 
obstruction flatus and stool are absent [4].
Management
The management of MBO is difficult, complicated and involves a specific and individualized 
approach to each patient. Multiple studies have reported surgery as the best option to improve 
survival and management of symptoms, but not appropriate in all patients due to its high 
perioperative mortality and post-operative complications [5 6].
Placement of a self-expandable metal stent (SEMS) is an accepted therapeutic option for palliation 
of malignant obstruction involving the esophagus, gastro-duodenum, and colon. Introduction of 
stenting for palliative management has not improved survival but hospital stay is shortened. 
Despite high technical success with palliative stenting, it is feasible only in specific situations. 
Complications include perforation, migration, bleeding and obstruction [2 7]. Contraindications to 
stenting include poor performance status, poor prognosis (< 30 days), bowel perforation, bowel 
stenosis, multiple sites of obstruction, and peritoneal carcinomatosis [4].
Octreotide is a somatostatin analogue that inhibits vasoactive intestinal polypeptide activity in the 
gut, thereby reducing gastric and pancreatic juices and water and electrolyte excretion in the 
lumen.[3, 7] It also reduces splanchnic blood flow, indirectly decreasing gut wall edema, peristalsis 
(and secondary abdominal cramping), and bile excretion. Octreotide has been shown to improve 
bowel obstruction symptoms, sometimes eliminating the need for surgery, or improving the 
outcome of surgery by minimizing gut wall damage such as necrosis. Palliative patients might 
even have reversal of the subocclusive process [3 8 9].
Dexamethasone acts as an anti-inflammatory by decreasing gut wall edema, thereby relieving 
some of the stenosis and decreasing the excretion of water into the lumen [4]. Both of these actions 
can improve pain levels. It also has a central antiemetic effect.
Metoclopramide, a prokinetic of the stomach and small bowel and is often used first line to control 
nausea in the setting of partial bowel obstruction. Retrospectively, and clinically, when used in 
combination with octreotide and dexamethasone it is effective in patients achieving de-obstruction 
with low to minimal risk of perforation.
The use of the triple regimen together has not been yet done prospectively.
Evidence for Palliative Medical Management
Most cases of MBO are not surgical emergencies hence, medical therapy should always be 
considered initially as the picture becomes clear with passage of time. Baines et al [10] 
demonstrated successful management of 38 cases of MBO with medical treatment. Similar 
outcomes were demonstrated by several other authors [11]. In 1992, Mercedante et al. showed 
efficacy of octreotide in several cases of MBO in the resolution of intractable nausea and vomiting 
[12]. Since then multiple observational and case series support the efficacy of octreotide in the 
management of nausea and vomiting of MBO [13 14]. In a double-blinded, randomized placebo-
controlled trial, there was no reduction in vomiting-free days with the addition of octreotide to a 
standardized regimen of dexamethasone, ranitidine and fluids in malignant bowel obstruction [15].
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 6 of 46
A retrospective study of MBO patients treated with octreotide, metoclopramide, and 
dexamethasone showed rapid improvement in nausea, and moderate/severe abdominal pain [16]. 
Metoclopramide has been studied in bowel obstruction in multiple studies but is usually 
recommended in partial obstruction and avoided in complete obstruction. Clinically, in the setting 
of MBO it is often difficult to decipher if a patient has complete or partial obstruction-imaging 
may not be accurate or reflective of the clinical picture. The general clinical rule of thumb is if 
there is flatus, it is a partial obstruction. In two retrospective studies when metoclopramide was 
given to patients with (complete or partial) MBO there was no incidence of perforation or increased 
colicky pain [8 16] Maximal effectiveness may not be reached until doses well in excess of 
30 mg/day are given [5]. Due to a low risk of bowel perforation, especially in partial bowel 
obstruction, cautious use is recommended and the drug should be stopped immediately if pain 
worsens [4].
2.2
Rationale
Venting gastrostomies should be considered for patients with unresolved and symptomatic MBO 
depending on the clinical condition and patient’s choice. They can be very effective at relieving 
nausea and vomiting, and usually better tolerated than nasogastric tubes. It may enable patients to 
eat and drink and to be cared for at home [17-20]. Contraindications to percutaneous gastrostomy 
include portal hypertension, massive ascites, active gastric ulceration and active bleeding [4].
Despite this progress there are few prospective studies and published guidelines for the medical 
management of inoperable MBO. Standard treatment involves bowel rest, intravenous fluids, pain 
medications and surgery if possible. The current proposed drug regimen has been studied 
retrospectively [16] but is not the standard of care for medical management. Metoclopramide has 
been traditionally avoided in the setting of complete bowel obstruction for concern for risk of 
perforation. However, in some retrospective studies and in years of clinical experience in the field, 
when using this drug in this population, the incidence is extremely rare [8 16].
We feel that the addition of metoclopramide to the other two drugs is a key for the efficacy of the 
medical management for MBO to be effective. The prognosis for patients who remain obstructed 
with venting G-tubes and TPN is often weeks to a few months; the benefits of de-obstruction is 
great, and the risks are minimal. The PI of this study surveyed five national palliative leaders who 
have studied MBO and work in oncology and they all use the triple regimen commonly, for many 
years with minimal adverse effects. The PI also discussed the use of the triple therapy with a three 
local GI medical oncologists, three GI surgical oncologists, a radiologist, 3 GYN oncologists and 
four hospitalists who all have been exposed to this regimen for the past 3 years at Roswell Park as 
we currently use it successfully for our patients who have MBO. We retrospectively examined 
data from 2015-2018 of 68 total patients: 34 who received the triple therapy compared to 34 who 
received no medications. Patients who received the triple therapy were twenty times more likely 
to reach de-obstruction, compared with patients who were given no medications (OR: 20.73 with 
95% CI [1.99, 215.86], P=0.0112), after adjusting for related covariates. Only 3 patients in the 
triple therapy group had complete obstructions and there were no patients who had a reported 
bowel perforation after receiving the triple therapy. 
We plan to study all three drugs for all patients with partial obstruction and exclude those with 
complete obstruction. If a patient develops worsened pain after administration of metoclopramide, 
this drug would be immediately discontinued.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 7 of 46
The objectives of the current study are to analyze the rate of de-obstruction and effects on symptom 
control with use of medical regimens for malignant bowel obstruction prospectively.
3
INCLUSION AND EXCLUSION CRITERIA
NOTE: Patients requiring a gastrostomy tube insertion or with a prior gastrostomy tube will not 
be excluded.
3.1
Inclusion Criteria
To be included in this study, participants must meet the following criteria:
1
Age ≥ 18 years of age.
2
Diagnosis of partial bowel obstruction secondary to active or prior malignancy (primary or 
metastatic GI, GYN, and carcinomatosis) caused either by tumor itself or adhesions in the 
setting of active malignancy.
3
Cross-sectional imaging performed within 24 hours of clinical symptoms of bowel 
obstruction (nausea, vomiting, and constipation ± abdominal pain) during hospital 
admission.
4
Patient must have an inoperable MBO.
5
Participant must understand the investigational nature of this study and sign an Independent 
Ethics Committee/Institutional Review Board approved written informed consent form 
prior to receiving any study related procedure.
Refer to Appendix A: for the ELIGIBILITY VERIFICATION FORM: INCLUSION 
CRITERIA checklist.
3.2
Exclusion Criteria
Participants will be excluded from this study for the following:
1
Evidence of complete bowel obstruction by imaging.
2
Bacteremia/septicemia with a documented positive blood culture: If a blood culture comes 
back positive after study enrollment, patient will be excluded.
3
Patients already taking a steroid equivalent to 8 mg of dexamethasone per day for longer 
than 7 days prior to study enrollment.
4
Patients undergoing bowel surgery or stent placement for bowel obstruction.
5
Those patients with MBO in setting of incarcerated hernia.
6
Known history of QT prolongation syndrome or if QTc is > 500 msec on baseline EKG 
within 2 weeks of enrollment.
7
Lack of decision-making capacity/delirium.
8
Pregnant or nursing female participants.
9
Actively suicidal patients.
10 Acute cholecystitis.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 8 of 46
11 History of seizure episode in the last 12 months or patient on a maintenance antiepileptic 
drug for seizure control.
12 Acute pancreatitis.
13 Bowel perforation.
14 Patients taking antipsychotic drugs.
15 History of dystonia or tardive dyskinesia.
16 Patients with pheochromocytoma.
17 Elevated blood pressure 180 mmHg systolic or 120 mmHg diastolic.
18 Immunocompromised patients.
19 Patients with latent tuberculosis history.
20 Incarcerated patients.
21 Patient already enrolled in a clinical trial.
22 Unwilling or unable to follow protocol requirements.
23 Any condition which in the Investigator’s opinion deems the participant an unsuitable 
candidate to receive study treatment.
Refer to Appendix B for the ELIGIBILITY VERIFICATION FORM: EXCLUSION 
CRITERIA checklist.
3.3
Inclusion of Women and Minorities
Both men and women and members of all races and ethnic groups are eligible for this study.
4
LOCAL AND STUDY-WIDE NUMBER OF SUBJECTS
A maximum of 59 participants at Roswell Park will be enrolled prospectively. Accrual is expected 
to take 3 years.
5
LOCAL AND STUDY-WIDE RECRUITMENT METHODS
The Clinical Research Coordinator will be notified  by the participating services (GYN, surgical 
and hospitalist) of any new admissions of patients presenting with bowel obstruction secondary to 
malignancy that may meet the study criteria (educational in-service will need to be conducted prior 
to study initiation on what criteria need to be met to identify potential study participants). Once a 
potential study participant is identified, a palliative care consult will be ordered, and the patient 
will be seen as usual in consultation by the palliative care service when a consult is ordered. They 
will remain as an inpatient under the primary service. The Clinical Research Coordinator will 
communicate with the primary team as well as the study personnel about study related changes to 
the treatment of the patient.
6
MULTI-SITE RESEARCH
Not applicable. This is a single-site study.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 9 of 46
7
STUDY TIMELINES
Patients that are admitted with a bowel obstruction at Roswell Park and that meet the study 
eligibility requirements will be enrolled after signing an informed consent and, will be started on 
the drug regimen according to the type of bowel obstruction.
Day 1 will be identified as the day of start of treatment.
Patients will be followed for de-obstruction up to 7 days while on inpatient treatment.
If the patient de-obstructs within 7 days of starting treatment (as an inpatient), then they will 
continue the triple regimen for the full 7 days or until discharged.  At that time, octreotide will be 
discontinued, and the metoclopramide and dexamethasone will be switched to oral for another 3 
days, for a total of 10 days.
During the 3 days following discharge:

Patients will be followed daily through phone calls by the Clinical Research Coordinator 
until they complete the 3-day post de-obstruction treatment (± 2 days) with the oral 
regimen. If the discharge occurs on a weekend day or holiday, the Clinical Research 
Coordinator will commence daily follow-up on the first business day following discharge 
and will continue until the patient has completed the 10 days of treatment.  If completion 
of the 3-day post-de-obstruction treatment occurs on a weekend day or holiday, the Clinical 
Research Coordinator will follow-up with the patient within 2 days following the 3-day 
post-de-obstruction treatment completion time point.
o
Evaluation will include monitoring adverse events, treatment administration and 
recording the treatment administration data.
If the patient is discharged prior to 7 days, octreotide will be discontinued, and the metoclopramide 
and dexamethasone will be switched to oral until the 10-day treatment is complete.  
If the patient is inpatient for over 7 days and up to 10 days, continue octreotide, metoclopramide, 
and dexamethasone treatment for up to 10 days. If the patient is then discharged prior to day 10, 
continue metoclopramide and dexamethasone orally until the 10-day treatment is complete. 
If de-obstruction does not occur as inpatient, the clinician may choose to stop the drug regimen 
and a surgical/endoscopic consultation will be obtained to evaluate for possible venting G-tube 
placement.
8
STUDY ENDPOINTS
8.1
Primary Endpoint

The primary efficacy endpoint is the proportion of eligible patients whose malignant bowel 
obstruction clears (de-obstruction) within 7 days of starting the protocol therapy. Patients 
meeting de-obstruction criteria within 7 days will be deemed treatment successes.

De-obstruction is defined as:
o
Effective introduction of oral intake (yes/no) 

Distinguished from small volumes of oral fluid that may be allowed with 
unresolved MBO
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 10 of 46

Tolerating oral liquid diet (Day 1 of de-obstruction) that is able to be 
progressively more solid (oral or enteral)

Cessation of vomiting or ability for NGT or venting G tube to remain 
clamped without vomiting

The resumption of bowel movements

Rate of de-obstruction is defined as:
o
From the date of study enrollment to the first observation of de-obstruction.
8.2
Secondary Endpoints

Factors that may affect treatment with the treatment regimen will be determined by 
measuring/assessing the following:
o
Oral intake
o
NG/PEG output
o
Effect on symptom control:

pain

nausea

vomiting

constipation
o
Disposition upon discharge:

Discharged home

Hospice in any setting

LTC (Long Term care) or SAR (Sub-acute Rehabilitation)

Overall survival (OS) will be measured from the date of study enrollment to the time of 
death from any cause in 6 months.
9
DESIGN
This is a prospective, open-label, single-center, Phase 2 study to identify the role of palliative 
management of inoperable malignant bowel obstruction. The study schema is depicted in Figure 
1 on the next page.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 11 of 46
Figure 1
Screen for Eligibility
Excluded 
Included
Inoperable malignant 
bowel obstruction
Triple Regimen:
1. Octreotide 300mcg IV TID
2. Metoclopramide 10mg IV q6h
3. Dexamethasone 4mg IV am and mid-day 
De-obstruction occurs 
within 7 days 
De-obstruction does 
not occur within 7 
days
Adverse event occurs 
within 7 days
Continue triple regimen for 
up to 10 days while inpatient.  
If patient is discharged prior 
to Day 10, continue 
dexamethasone and 
metoclopramide orally until 
the 10-day treatment period is 
complete.
Stop the treatment and 
obtain consult for 
venting G tube 
placement
Record the adverse 
event and decide on 
holding or 
discontinuing the 
offending drug or drugs 
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 12 of 46
Patents will be screened for eligibility on admission (i.e., presence of malignant bowel obstruction) 
and if eligible and agreeable to participate, will be enrolled.
Complete obstruction is diagnosed clinically (vomiting, pain, abdominal distention, anorexia, 
absence of stools or flatus) and verified with X-ray or CT scan. These patients would be excluded. 
Partial obstruction would be diagnosed clinically (with some of the same above symptoms but also 
passing flatus) along with CT scan findings.
Patients will receive a triple regimen consisting of IV octreotide + IV dexamethasone + IV 
metoclopramide. If the patient reports worsening severe abdominal pain after administration of 
metoclopramide they will be assessed, and it will be decided if the drug be discontinued. 
Patients will be monitored throughout the course of hospitalization and time to de-obstruction will 
be recorded.
10 TREATMENT
10.1 Dosing and Administration
Triple drug regimen for bowel obstruction: IV octreotide 300 mcg TID + IV dexamethasone 4 mg 
BID (first dose 9am and second at 2pm) + IV metoclopramide 10 mg q6h.

In patients with a creatinine clearance (CrCl) of < 40 mL/min, the metoclopramide dose 
will be reduced to 5 mg q6 hours.

For patients ≥ 65 years of age, the metoclopramide dose will be reduced to 5 mg q6 hours.
The patient will continue on study treatment for up to 10 days or until de-obstruction (whichever 
occurs first), de-obstruction is defined in section 8.1.
If de-obstruction occurs within 7 days of treatment initiation:

Continue treatment regimen while inpatient for up to 10 days.  If they are discharged before 
7 days, octreotide would be discontinued, and they would continue metoclopramide and 
dexamethasone orally until the 10-day treatment period is complete.  

If the patient is inpatient for over 7 days up to 10 days continue octreotide, 
metoclopramide, and dexamethasone for up to 10 days. If the patient is discharged prior 
to Day 10, continue metoclopramide and dexamethasone orally until the 10-day treatment 
period is complete. 
If de-obstruction does not occur within 7 days of treatment initiation:

At the discretion of the clinician, treatment regimen can be stopped, and a surgical/IR 
consult obtained for possible venting g-tube placement
If an adverse event occurs within 7 days of treatment initiation:

Decision will be made to hold or discontinue drug/drugs
Reported adverse events (AEs) and potential risks are described in Section 13. 
Treatment is intended for an inpatient setting.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 13 of 46
10.2 Dose Modifications and Management of Adverse Events
10.2.1 Dexamethasone
Note: Starting dose of dexamethasone is 4 mg BID. For the management of adverse events the 
dose of dexamethasone can be reduced by one-half (e.g., the first dose reduction would be 2 mg 
BID: 2 mg in the morning and 2 mg in the afternoon).

Delirium: Screen with Condensed Memorial Assessment Scale (CMAS) and Confusion 
Assessment Method-Short Form (CAM-S) daily (Acute onset and fluctuating course, 
inattention, disorganized thinking, altered level of consciousness) [21]. Nursing staff 
would screen for delirium over the weekend. Discontinue dexamethasone.

Fever: Monitor temperature daily. If there is a documented temperature of > 100.4°F, then 
stop dexamethasone.

Hyperglycemia: Monitor blood sugar every day. If blood glucose is > 200 mg/dL, then 
activate sliding scale insulin protocol for insulin naïve patients. For patients already on 
insulin, increase the dose of insulin (clinical discretion of physician).

Increased risk of infections: Monitor clinically and follow leukocyte count based on 
clinical discretion. The leukocyte count is expected to rise with the use of dexamethasone, 
and it would be up to the physician to pursue infectious work up if an infection is suspected. 
Stop dexamethasone if infection is suspected.

Hypertension: May occur with dexamethasone. Dose reduction or discontinuing the drug 
would be based on clinical discretion of the physician.

Body fluid retention or peripheral edema: May occur with dexamethasone. Dose 
reduction or discontinuing the drug would be based on clinical discretion of the physician.

Depression: May occur with dexamethasone. Dose reduction or discontinuing the drug 
would be based on clinical discretion of the physician.

Increased risk of tuberculosis: May occur with dexamethasone. Discontinue 
dexamethasone if TB is suspected.

Skin irritation: May occur with dexamethasone. Dose reduction or discontinuing the drug 
would be based on clinical discretion of the physician.

Cushing syndrome: May occur with dexamethasone. Discontinue dexamethasone if 
Cushing’s syndrome develops.

Cardiomyopathy: May occur with dexamethasone. Dose reduction or discontinuing the 
drug would be based on clinical discretion of the physician.

Bowel perforation: May occur with dexamethasone. Discontinue triple regimen and 
withdraw patient from the study.

Compression fracture: May occur with dexamethasone. Dose reduction or discontinuing 
the drug would be based on clinical discretion of the physician.

Cerebrovascular accident:  May occur with dexamethasone. Discontinue triple regimen 
and withdraw patient from the study.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 14 of 46

Infarction of spinal cord: May occur with dexamethasone. Discontinue triple regimen 
and withdraw patient from the study.

Nerve injury: May occur with dexamethasone. Discontinue dexamethasone.

Paraplegia: May occur with dexamethasone. Discontinue triple regimen and withdraw 
patient from the study.

Raised intracranial pressure: May occur with dexamethasone. Discontinue 
dexamethasone.

Seizure: May occur with dexamethasone. Discontinue dexamethasone.

Tetraplegia: May occur with dexamethasone. Discontinue triple regimen and withdraw 
patient from the study.

Blindness and/or vision impairment level: May occur with dexamethasone. Discontinue 
triple regimen and withdraw patient from the study.

Cortical blindness: May occur with dexamethasone. Discontinue triple regimen and 
withdraw patient from the study.
10.2.2 Metoclopramide

Extrapyramidal symptoms: Monitor for development of involuntary movements, cog-
wheel rigidity, severe irritability, personality change. If suspected, stop metoclopramide 
and if acute dystonic reaction, which is rare and may manifest with involuntary movements 
of limbs, facial grimacing, torticollis, rhythmic protrusion of tongue, dystonic reactions or 
difficulty breathing may give diphenhydramine 50 mg IV or IM.

QT prolongation: Monitor EKG after 7 days on study. If QT is > 500 msec, then stop 
metoclopramide.

Severe Abdominal Pain (Score of 7 or greater on Likert scale): If abdominal pain 
occurs or worsens within 1-15 minutes of metoclopramide administration, then the drug 
would be withheld for the rest of the study. The onset of pharmacological action of 
metoclopramide is 1 to 3 minutes following an intravenous dose.

Bowel perforation: May occur with metoclopramide. Discontinue triple regimen and 
withdraw patient from the study.

Neuroleptic malignant syndrome: Neuroleptic malignant syndrome (NMS) may occur 
with metoclopramide. Discontinue the drug if NMS is suspected. 

Tardive dyskinesia: Tardive dyskinesia (TD) may occur with metoclopramide. 
Discontinue the drug if TD is suspected.

Seizure disorder: This drug may lower the seizure threshold.
10.2.3 Octreotide:
Note: For the management of adverse effects, octreotide may be held for a minimum of 24 hrs and 
then followed by patient reassessment.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 15 of 46
Dose Reduction: The starting dose of octreotide is 300 mcg TID. For the management of adverse 
events the dose of octreotide can be reduced by 100 mcg TID (e.g., the first dose reduction would 
be 200 mcg TID: 200 mcg in the morning, 200 mcg in the afternoon and, 200 mcg in the evening).

Hypoglycemia: Monitor blood sugar every day. If blood glucose is < 60 mg/dL, then 
activate hypoglycemia protocol (refer to Appendix E:).

Nausea: May occur with octreotide. Dose reduction or holding the drug would be based 
on clinical discretion of the physician.

Backache: May occur with octreotide. Dose reduction or holding the drug would be based 
on clinical discretion of the physician.

Dizziness: May occur with octreotide. Dose reduction or holding the drug would be based 
on clinical discretion of the physician.

Headache: May occur with octreotide. Dose reduction or holding the drug would be based 
on clinical discretion of the physician.
Fatigue: May occur with octreotide. Dose reduction or holding the drug would be based on clinical 
discretion of the physician.

Flatulence: May occur with octreotide. Dose reduction or holding the drug would be based 
on clinical discretion of the physician.

Hypothyroidism: May occur with octreotide. Dose reduction or holding the drug would 
be based on clinical discretion of the physician.

Bradycardia: Bradycardia may occur with octreotide. Dose reduction or holding the 
drug would be based on clinical discretion of the physician.
10.2.4 Allergic reaction to octreotide, dexamethasone, or metoclopramide
Dexamethasone: Signs of an allergic reaction to dexamethasone include hives; difficulty 
breathing, swelling of ace, lips, tongue, or throat.
Metoclopramide: Symptoms of an allergic reaction to metoclopramide can include rash, hives, 
trouble breathing, and swelling of tongue, lips, or throat.
Octreotide: Although urticaria, allergy/hypersensitivity reactions and anaphylaxis have been 
noted as possible adverse reactions, there is a lack of data showing a causal relationship between 
octreotide and hypersensitivity reactions and there is no information on management when 
continued use of this medication is essential.
**Management of allergic reactions**
Based on the specific symptoms of the reaction, the identified offending medication would be 
discontinued, and the allergic reaction would be treated as appropriate.
10.3 General Concomitant Medication and Supportive Care
Patients may receive anti-emetics, opioid pain medications for pain control and, antibiotics for 
infection, if necessary. If a patient develops a clinical condition unrelated to the study, then they 
may be withdrawn from the study (to be determined by the principal investigator).
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 16 of 46
10.4 Duration of Treatment
Participants will be on the study drug combination for a maximum of 10 days as an inpatient in 
the absence of disease progression, unacceptable toxicity and withdrawal from study, intercurrent 
illness that prevents further administration of treatment, participant demonstrates an 
inability/refusal to comply with the medication regime or, participant withdraws from study. 
If de-obstruction occurs within the 7 days, upon discharge, the patient will receive an additional 
3 days of the treatment combination as an outpatient, for a total of 10 days of treatment.
11 PROCEDURES INVOLVED
11.1 Participant Registration
Eligibility of each participant will be established prior to registration
Informed consent MUST be completed prior to receiving any study related procedures.
11.2 Pre-treatment Screening

Medical history (including all prior therapy related to malignant bowel obstruction)
o
Cancer stage and primary diagnosis date
o
Comorbidity index score
o
Surgical history
o
MBO symptoms

Weight and BMI

Blood draw to determine Plasma Creatinine clearance using the Cockcroft-Gault formula:

Smoking/ alcohol use history

Prior use of steroids (include use for up to 1 month prior to hospitalization)

Karnofsky score (refer to Appendix D)

Concomitant Medications
Mandatory Pre-treatment Evaluations

Baseline EKG (not necessary if one is available that was taken no later than 2 weeks prior 
to study registration)

Pregnancy test (B-HCG) in females of childbearing potential
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 17 of 46
11.3 Evaluations Performed during Inpatient Treatment
The following research procedures will be performed up to Day 7 of Inpatient Treatment

Condensed Memorial Assessment Scale

Confused Assessment Method – Short Form

Blood sugars will be performed every day

Adverse event monitoring will be ongoing and recorded daily while on study treatment
The following standard of care procedures may be considered (depending on the clinical discretion 
of the physician) during the treatment, but are not mandatory:

NG tube insertion

IV line insertion

G-tube insertion

Venting G-tube insertion

Imaging (CT scan or X-ray)
11.4 Evaluations Performed Prior to Discharge
The following evaluations will be performed at the end of 7 days (prior to discharge, ± 3 days) or 
at time of treatment discontinuation:

EKG

Concomitant medication

Adverse events
11.5 Discharge Follow-up
Treatment continuation will be done as an outpatient if the patient is stable for discharge as 
determined by the physician. During the days following discharge:

If the patient de-obstructs, the drug regimen will be transitioned to oral in the case of 
metoclopramide and dexamethasone while octreotide will be discontinued.

Patients will be followed daily through phone calls by the Clinical Research Coordinator 
until they complete the post de-obstruction treatment (± 2 days) with the triple regimen. If 
the discharge occurs on a weekend day or holiday, the Clinical Research Coordinator will 
commence daily follow-up on the first business day following discharge and will continue 
until the patient has completed the triple regimen post-de-obstruction treatment. If 
completion of the post-de-obstruction treatment occurs on a weekend day or holiday, the 
Clinical Research Coordinator will follow-up with the patient within 3 days following the 
post-de-obstruction treatment completion time point.

Evaluation will include monitoring adverse events, treatment administration and recording 
the treatment administration data.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 18 of 46
11.6 Post-Treatment Follow-Up Evaluations
Follow-up safety evaluations will occur 30 days (± 3 days) after last dose of study drug or until 
resolution of any drug-related toxicity (telephone contact is acceptable).

Concomitant medications: List any ongoing medications with dose changes, as applicable.

Adverse events
11.7 Long Term Follow-Up Evaluations
Long-term follow up will be done at 3 month and 6 months from the time of discharge by follow-
up phone call (to include tolerance of oral intake, bowel movements, hospitalizations).
Participants who are unavailable for follow-up evaluations should be classified as lost to follow-
up for 1 of the following reasons:

Lost to follow-up: For a participant to be considered lost to follow-up, the investigator must 
make two separate attempts to re-establish contact with the participant. The attempts to re-
establish participant contact must be documented (e.g., certified letter).

Death: Date and cause of death will be recorded for those participants who die within 
30 days after last dose of study drug (telephone verification is acceptable).
12 WITHDRAWAL OF SUBJECTS
Participants will be withdrawn from the study if any of the following occurs:

Allergic reaction to octreotide, dexamethasone, or metoclopramide

Occurrence of any of the following while receiving the triple-drug regimen:
o
Bowel perforation
o
Cerebrovascular accident
o
Infarction of spinal cord
o
Paraplegia
o
Tetraplegia
o
Blindness and/or vision impairment level
o
Cortical blindness

The patient can voluntarily withdrawal for any reason or, due to any unacceptable toxicity 
based on the PI’s decision.
12.1 Treatment Discontinuation
Upon treatment discontinuation all end of treatment evaluations and tests will be conducted. All 
participants who discontinue due to an AE must be followed until the event resolves or stabilizes. 
Appropriate medical care should be provided until signs and symptoms have abated, stabilized, or 
until abnormal laboratory findings have returned to acceptable or pre-study limits. The final status 
of the AE will be reported in the participant’s medical records and the appropriate eCRF.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 19 of 46
Reasons for treatment discontinuation should be classified as follows:

Death

Progressive disease

Toxicity: treatment related or unrelated

Investigator judgment
o
The Investigator may discontinue a participant if, in his/her judgment, it is in the 
best interest of the participant to do so.

Participant voluntary withdrawal
o
A participant may withdraw from the study at any time, for any reason. If a 
participant discontinues treatment, an attempt should be made to obtain 
information regarding the reason for withdrawal.
13 RISKS TO SUBJECTS
The drug regimens proposed for the study consist of octreotide, dexamethasone, and 
metoclopramide. These drugs are not experimental and have been FDA approved for various 
clinical conditions.
13.1 Dexamethasone
Dexamethasone sodium phosphate (dexamethasone) is an adrenocortical steroid anti-
inflammatory drug.
Reported common adverse effects related to dexamethasone include:

Cardiovascular: Hypertension (Diabetic macular edema, 13%)

Dermatologic: Atrophic condition of skin, Finding of skin healing, Impaired

Endocrine metabolic: Cushing's syndrome, Decreased body growth

Ophthalmic: Abnormal vision (1% to 9%), Cataract (Diabetic macular edema, 68%; 
retinal vein occlusion and uveitis, 5%), Conjunctival edema (5% ), Conjunctivitis (6%), 
Corneal edema (5% to 15% ), Discomfort, Eye (10% ), Dry eye syndrome (5%), Iritis (5% 
to 15%), Raised intraocular pressure (Diabetic macular edema, 35%; retinal vein occlusion 
and uveitis, 25% ; postoperative inflammation, 5% to 15%), Vitreous floaters (1% to 5%)

Psychiatric: Depression, Euphoria

Respiratory: Pulmonary tuberculosis
Reported serious adverse effects related to dexamethasone include:

Cardiovascular: Cardiomyopathy

Endocrine metabolic: Hyperglycemia, Primary adrenocortical insufficiency

Gastrointestinal: Pancreatitis

Immunologic: Infectious disease

Musculoskeletal: Osteoporosis
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 20 of 46

Ophthalmic: Conjunctival hemorrhage (Diabetic macular edema, 23%; retinal vein 
occlusion and uveitis, 22%), Glaucoma (Diabetic macular edema, 1.2%), Keratitis (2%), 
Posterior subcapsular cataract, Retinal tear (2%), Retinal vascular disorder (3%), Uveitis 
(2%)
13.2 Metoclopramide
Metoclopramide is classified as a dopamine-receptor antagonist. Metoclopramide stimulates 
motility of the upper gastrointestinal tract and, increases the tone and amplitude of gastric 
(especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases 
peristalsis of the duodenum and jejunum.
The most common adverse reactions reported for metoclopramide (> 10%) are restlessness, 
drowsiness, fatigue, and lassitude.
13.3 Octreotide
Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin and, is 
indicated for treatment of acromegaly, carcinoid tumors and, vasoactive intestinal peptide tumors 
(VIPomas).
The most common adverse reactions reported for octreotide, occurring in ≥ 20% of patients are:

Acromegaly: diarrhea, cholelithiasis, abdominal pain, flatulence 

Carcinoid Syndrome: back pain, fatigue, headache, abdominal pain, nausea, dizziness
14 POTENTIAL BENEFITS TO SUBJECTS

Patients who have inoperable MBO are not able to eat by mouth and often require a venting 
PEG tube and TPN to maintain nutrition which is associated with increased morbidity and 
mortality, with reduced prognosis and quality of life.

If we are able to relieve the MBO, preventing them from having a venting PEG tube and/or 
TPN, they would be able to eat food by mouth for pleasure and nutrition. They would have 
reduced risk for infections due to TPN and pain from PEG tube insertion and discomfort 
at the site.
15 DATA AND SPECIMEN BANKING
Not Applicable.
16 MEASUREMENT OF EFFECT
Rate of de-obstruction:

Defined date of study enrollment to the first observation of clearance or de-obstruction.
Patients meeting de-obstruction criteria within 7 days will be deemed treatment successes.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 21 of 46
17 SAFETY EVALUATION
17.1 Adverse Events
An adverse event or adverse experience (AE) is any untoward medical occurrence associated with 
the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be ANY 
unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or not 
considered related to the medicinal (investigational) product (attribution of ‘unrelated’, ‘unlikely’, 
‘possible’, ‘probable’, or ‘definite’).
An AE is considered “unexpected” if it is not listed in the investigator brochure or is not listed at 
the specificity or severity that has been observed; or if an investigator brochure is not required or 
available, is not consistent with the risk information described in the general investigational plan 
in other study-related documents.
17.1.1 Diagnosis Versus Signs and Symptoms
If known, a diagnosis should be recorded on the CRF rather than individual signs and symptoms 
(e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and elevated 
transaminases). However, if a constellation of signs and/or symptoms cannot be clinically 
characterized as a single diagnosis or syndrome at the time of reporting, each individual event 
should be recorded as an AE or SAE on the CRF. If a diagnosis is subsequently established, it 
should be reported as follow-up information.
17.1.2 Adverse Events Occurring Secondary to Other Events
In general, AEs occurring secondary to other events (e.g., cascade events or clinical sequelae) 
should be identified by their primary cause. For example, if severe diarrhea is known to have 
resulted in dehydration, it is sufficient to record only diarrhea as an AE or SAE on the CRF.
However, clinically significant AEs occurring secondary to an initiating event that are separated 
in time should be recorded as independent events on the CRF. For example, if a severe 
gastrointestinal hemorrhage leads to renal failure, both events should be recorded separately on 
the CRF.
17.1.3 Abnormal Laboratory Values
Only clinically significant laboratory abnormalities that require active management will be 
recorded as AEs or SAEs on the CRF (e.g., abnormalities that require study drug dose 
modification, discontinuation of study treatment, more frequent follow-up assessments, further 
diagnostic investigation, etc.).
If the clinically significant laboratory abnormality is a sign of a disease or syndrome (e.g., alkaline 
phosphatase and bilirubin 5 x the upper limit of normal associated with cholecystitis), only the 
diagnosis (e.g., cholecystitis) needs to be recorded on the Adverse Event CRF.
If the clinically significant laboratory abnormality is not a sign of a disease or syndrome, the 
abnormality itself should be recorded as an AE or SAE on the CRF. If the laboratory abnormality 
can be characterized by a precise clinical term, the clinical term should be recorded as the AE or 
SAE. For example, an elevated blood potassium level of 7 mEq/L should be recorded as 
“hyperkalemia”.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 22 of 46
Observations of the same clinically significant laboratory abnormality from visit to visit should 
not be repeatedly recorded as AEs or SAEs on the CRF, unless their severity, seriousness, or 
etiology changes.
Preexisting Medical Conditions (Baseline Conditions)
A preexisting medical condition should be recorded as an AE or SAE only if the frequency, 
severity, or character of the condition worsens during the study. When recording such events on 
an Adverse Event CRF, it is important to convey the concept that the preexisting condition has 
changed by including applicable descriptors (e.g., “more frequent headaches”).
17.2  Grading and Reporting Adverse Events
17.2.1 Grading and Relationship to Drug
The descriptions and grading scales found in the CTEP Version 5 of the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting. CTEP 
Version 5.0 of the CTCAE is identified and located at:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
AEs not covered by specific terminology listed should be reported with common medical 
terminology and documented according to the grading scales provided in the CTCAE Version 5.
The relationship of event to study drug will be documented by the Investigator as follows:

Unrelated: The event is clearly related to other factors such as the participant’s clinical 
state, other therapeutic interventions or concomitant drugs administered to the participant.

Unlikely: The event is doubtfully related to investigational agent(s). The event was most 
likely related to other factors such as the participant’s clinical state, other therapeutic 
interventions, or concomitant drugs.

Possible: The event follows a reasonable temporal sequence from the time of drug 
administration but could have been produced by other factors such as the participant’s 
clinical state, other therapeutic interventions, or concomitant drugs.

Probable: The event follows a reasonable temporal sequence from the time of drug 
administration and follows a known response pattern to the study drug. The event cannot 
be reasonably explained by other factors such as the participant’s clinical state, therapeutic 
interventions, or concomitant drugs.

Definite: The event follows a reasonable temporal sequence from the time of drug 
administration, follows a known response pattern to the study drug, cannot be reasonably 
explained by other factors such as the participant’s condition, therapeutic interventions or 
concomitant drugs; AND occurs immediately following study drug administration, 
improves upon stopping the drug, or reappears on re-exposure.
17.3 Reporting Adverse Events
Routine AEs occurring between the start date of intervention until 30 days after the last 
intervention, or until the event has resolved, the study participant is lost to follow-up, the start of 
a new treatment, or until the study investigator assesses the event(s) as stable or irreversible, will 
be reported. New information will be reported after it is received.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 23 of 46
Guidelines for Routine Adverse Event Reporting for Pilot, Phase 2, and Phase 3 Studies 
(Regardless of Expectedness)
Attribution
Grade 1
Grade 2
Grade 3
Grade 4
Unrelated
X
X
Unlikely
X
X
Possible
X
X
X
X
Probable
X
X
X
X
Definite
X
X
X
X
17.4 Serious Adverse Events
A serious adverse event (SAE) is any adverse event (experience) that in the opinion of either the 
investigator or sponsor results in ANY of the following:

Death.

A life-threatening adverse event (experience). Any AE that places a participant or 
participants, in the view of the Investigator or sponsor, at immediate risk of death from the 
reaction as it occurred. It does NOT include an AE that, had it occurred in a more severe 
form, might have caused death.

Inpatient hospitalization or prolongation of existing hospitalization (for > 24 hours).

A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions.

A congenital anomaly or birth defect.

Important Medical Event (IME) that, based upon medical judgment, may jeopardize the 
participant, and may require medical or surgical intervention to prevent one of the 
outcomes listed above.
17.4.1 Reporting Serious Adverse Events
All new SAEs occurring from the date the participant signs the study consent until 30 days after 
the last intervention or a new treatment is started, whichever comes first, will be reported. The 
Roswell Park SAE Source Form is to be completed with all available information, including a brief 
narrative describing the SAE and any other relevant information. 
SAEs occurring after the 30-day follow-up period that the investigator determines to be possibly, 
probably, or definitely related to the study intervention should be reported.
SAEs that are unexpected and possibly, probably, or definitely related must be reported as an 
Unanticipated Problem. Please refer to Section 17.6 for details on reporting Unanticipated 
Problems.
17.5 Follow-Up for Serious Adverse Events
All related SAEs should be followed to their resolution, until the study participant is lost to 
follow-up, the start of a new treatment, or until the study investigator assesses the event(s) as stable 
or irreversible. New information will be reported when it is received.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 24 of 46
17.6 Unanticipated Problems
An Unanticipated Problem (UP) is any incident, experience, or outcome that meets all of the 
following criteria:

Unexpected (in terms of nature, severity, or frequency) given:
o
The research procedures that are described in the study-related documents, including 
study deviations, as well as issues related to compromise of participant privacy or 
confidentiality of data.
o
The characteristics of the participant population being studied.

Related or possibly related to participation in the research (possibly related means there is 
a reasonable possibility that the incident, experience, or outcome may have been caused by 
the procedures involved in the research).

Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized or if in relation to an AE is deemed Serious per Section 17.3.
17.6.1 Reporting Unanticipated Problems
The Reportable New Information (RNI) Form will be submitted to the CRS Quality Assurance 
(QA) Office within 1 business day of becoming aware of the Unanticipated Problem. After review, 
CRS QA Office will submit the RNI to the IRB.
When becoming aware of new information about an Unanticipated Problem, submit the updated 
information to CRS QA Office with an updated Reportable New Information Form. The site 
Investigator or designated research personnel will report all unanticipated problems to the IRB in 
accordance with their local institutional guidelines.
18 DATA MANAGEMENT AND CONFIDENTIALITY
18.1 Data Collection
A unique code will be assigned to each patient on the data collection sheet. The codes will not 
correspond to any patient identifiers. The data collection sheet will be saved and maintained in the 
SharePoint site which is password protected. A copy of the data collection sheet is attached 
(Appendix C:). Study data (for analysis) will be provided to the statistician in a SAS-compatible 
EXCEL file. 
The research data will not contain any patient identifiers. It will be secured from improper use and 
disclosures by granting access to data files to only personnel involved in the study, namely 
principal investigator, and the co-investigators. Any paper files containing identifiers will not be 
taken off Roswell Park premises. Subject identity will not be disclosed in the event of publication 
or sharing of data.
A “basic build” will be used to collect the required information for grant, DSMB and continuing 
review reporting.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 25 of 46
18.2 Maintenance of Study Documents
Essential documents will be retained per Roswell Park policy for 6 years from the study 
termination date. These documents could be retained for a longer period, however, if required by 
the applicable local regulatory requirements or by an agreement with Roswell Park.
18.3 Revisions to the Protocol
Roswell Park may make such changes to the protocol as it deems necessary for safety reasons or 
as may be required by the U.S. FDA or other regulatory agencies. Revisions will be submitted to 
the IRB/ERC for written approval before implementation.
18.4 Termination of the Study
It is agreed that, for reasonable cause, either the Roswell Park Investigators or the Sponsor, may 
terminate this study, provided a written notice is submitted within the time period provided for in 
the Clinical Trial Agreement. In addition, Roswell Park may terminate the study at any time upon 
immediate notice if it believes termination is necessary for the safety of participants enrolled in 
the study.
18.5 Confidentiality
All information provided to the Investigator by Roswell Park including preclinical data, protocols, 
CRFs, and verbal and written information, will be kept strictly confidential and confined to the 
clinical personnel involved in conducting this study, and no disclosure shall be made except in 
accordance with any right of publication granted to the Investigator. This information may be 
related in confidence to the IRB/ERC or other committee functioning in a similar capacity. No 
report or information about the study will be provided to anyone not involved in the study without 
consent of Roswell Park except if required by law.
19 STATISTICAL PLAN
This is a single arm, one-stage Phase II trial evaluating the role of palliative management of 
inoperable malignant bowel obstruction in palliative care patients presenting with bowel 
obstruction secondary to malignancy.
Statistical analysis will be performed by the Roswell Park Biostatistics & Bioinformatics 
Department.
Sample Size Determination
The sample size calculations are based on the primary analysis, which compares the clearance rate 
for the prospective cohort to a historic control using one-sided binomial exact tests.
The historic control rate using the standard of care for this patient population (i.e. patient 
presenting with inoperable bowel obstruction secondary to malignancy) is approximately 0.7. The 
study design has 80.9% power to detect a 0.85 clearance rate with the proposed triple therapy, 
while controlling to 5% the probability of erroneously finding a truly ineffective treatment as 
worthy of further research.
To account for patients that may be non-evaluable (i.e., survival outcome occurs prior to the 7-day 
evaluation for clearance), up to n=59 patients may be accrued for the prospective cohort.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 26 of 46
Demographics and Baseline Characteristics
Descriptive statistics (as appropriate: n, percent, mean, median, min and max) will be used to 
summarize demographic and baseline characteristics in the overall sample.
Primary Analyses
The primary objective is to evaluate the role of palliative medical management of inoperable MBO 
with as the proposed triple therapy in patients presenting with inoperable bowel obstruction 
secondary to malignancy. The primary outcome is obstruction clearance, where the malignant 
bowel obstruction clears within 7 days of starting the protocol therapy, which is treated as a 
dichotomous variable. Clearance will be summarized using frequencies and relative frequencies, 
with the clearance rate estimated using a 90% confidence interval obtained by Jeffrey’s prior 
method.
The efficacy of the proposed triple therapy will be assessed using a one-sided, one-sample 
binomial exact test about the following hypotheses:
 versus 
,
𝐻0: 𝜋≤𝜋0
𝐻𝐴: 𝜋> 𝜋0
where  is the true clearance rate of the proposed triple therapy and 
 is the historic clearance 
𝜋
𝜋0
rate for the standard of care.
For this patient population, we expect the clearance rate for the standard of care to be 
approximately 0.7 (
). If the true clearance rate of the proposed triple therapy is 0.85, then 
= 𝜋0
we’d consider the therapy promising.
Based on these characteristics, a sample size of n=49 evaluable patients with inoperable bowel 
obstructions secondary to malignancy will be enrolled. If 39 or fewer of these patients have 
clearance, the triple therapy will be declared ineffective, and the study terminated. If 40 or more 
patients have clearance, the triple therapy will be considered interesting for further study.
Secondary Analyses
The secondary objectives are to compare the time to clearance and OS in patients treated with the 
proposed therapies, and the safety and tolerability of the proposed therapies.
Time to clearance and OS will be treated as bivariate time-to-event outcomes. Time to clearance 
will be measured from the date of study enrollment to the first observation of clearance. OS will 
be measured from the date of study enrollment to the time of death from any cause. The time-to-
event outcomes will be summarized by cohort using standard Kaplan-Meier (KM) methods. 
Estimates of the median times will be obtained with 95% confidence intervals. The 3- and 6-month 
OS rates will be estimated with 95% confidence intervals.
The adverse events and toxicities will be summarized by grade using frequencies and relative 
frequencies.
The additional factors that may affect or be related to treatment regimen (such as symptom control, 
discharge disposition, etc.) will be summarized using the appropriate descriptive statistics. As 
exploratory analyses, associations between these factors and time to clearance or OS may be 
evaluated using Cox regression models, while associations with toxicity may be evaluated using 
logistic regression models.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 27 of 46
Exploratory Analysis
As exploratory analyses, sub-group analyses may be performed on the set of patients that present 
with A) complete and B) partial obstructions. The analyses described in the primary and secondary 
analyses would be performed in these sub-groups. Additionally, a comparison of clearance and 
toxicity rates may be performed using Fisher’s exact test; and a comparison of time to clearance 
or OS may be performed using the log-rank test.
Safety Analysis
All participants who receive any study treatment will be considered evaluable for toxicity using 
the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 
Adverse events and toxicities will be summarized by grade using frequencies and relative 
frequencies.
Interim Analyses and Criteria for Early Termination
No formal interim analysis is included in the design, given the severity of the condition and the 
limited number of alternative treatment options. The study will be monitored by the Roswell Park 
Data Safety and Monitoring Committee (DSMC), who may make recommendations about study 
continuation and termination.
20 PROVISIONS TO MONITOR THE DATA TO ENSURE THE SAFETY OF 
SUBJECTS
As per the Roswell Park Data Safety Monitoring Plan, the Roswell Park Data and Safety 
Monitoring Committee will assess the progress of the study, the safety data, and critical efficacy 
endpoints. The DSMC will review the study and will make recommendations that include but not 
limited to; (a) continuation of the study, (b) modifications to the design (c) suspension of or, (d) 
termination of the study.
21 VULNERABLE POPULATIONS
Not Applicable.
22 COMMUNITY-BASED PARTICIPATORY RESEARCH
Not Applicable.
23 SHARING OF RESULTS WITH SUBJECTS
Individual response data is shared with the participant as a part of their clinical care.
24 SETTING
Inpatients at Roswell Park, a tertiary cancer care center.
25 PROVISIONS TO PROTECT THE PRIVACY INTERESTS OF SUBJECTS
Any data, specimens, forms, reports, video recordings, and other records that leave the site will be 
identified only by a participant identification number (Participant ID, PID) to maintain 
confidentiality. All records will be kept in a limited access environment. All computer entry and 
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 28 of 46
networking programs will be done using PIDs only. Information will not be released without 
written authorization of the participant.
Data collection will not contain patient identifiers – these will be removed by the Clinical Research 
Coordinator assigned to the study and will be replaced with a unique code that is assigned to each 
patient on the data collection sheet.
26 RESOURCES AVAILABLE
Study funding: Alliance Foundation of Roswell Park.
27 PRIOR APPROVALS
Not Applicable.
28 COMPENSATION FOR RESEARCH-RELATED INJURY
If the subject believes they have been injured as a direct result of their participation in this research 
study, they will be advised to notify the Roswell Park Patient Advocate at (716) 845-1365 or the 
Study Doctor at (716) 845-8675.
Medical diagnosis and treatment for the injury will be offered, and a determination will be made 
regarding appropriate billing for the diagnosis and treatment of the injury. A financial counselor 
(716-845-3161) will be able to provide an explanation of coverage and to answer questions the 
subject may have regarding study related billing.
The subject is not prevented from seeking to collect compensation for injury related to malpractice, 
fault, or blame on the part of those involved in the research.
29 ECONOMIC BURDEN TO SUBJECTS
The participants will not be subject to any economic burden. Any mandatory tests, including EKG 
and B-HCG, will be covered by the study.
30 CONSENT PROCESS
This study will not be initiated until the protocol and informed consent document(s) have been 
reviewed and approved by a properly constituted Institutional Review Board (IRB) or Independent 
Ethics Committee (IEC). Each participant (or legal guardian) shall read, understand, and sign an 
instrument of informed consent prior to performance of any study-specific procedure. It is the 
responsibility of the investigator to ensure that the participant is made aware of the investigational 
nature of the treatment and that informed consent is given.
The Investigator is responsible for the retention of the participant log and participant records; 
although personal information may be reviewed by authorized persons, that information will be 
treated as strictly confidential and will not be made publicly available. The investigator is also 
responsible for obtaining participant authorization to access medical records and other applicable 
study specific information according to Health Insurance Portability and Accountability Act 
regulations (where applicable).
This study will be conducted in compliance with all applicable laws and regulations of the state 
and/or country and institution where the participant is treated. The clinical trial should be 
conducted in accordance with the ethical principles embodied in the Belmont Report: Ethical 
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 29 of 46
Principles and Guidelines for the Protection of Human Subjects of Research, consistent with good 
clinical practice and the applicable regulatory requirements and according to the guidelines in this 
protocol, including attached appendices.
31 PROCESS TO DOCUMENT CONSENT IN WRITING
Eligible patients would be screened electronically prior to study enrollment and informed consent 
would be obtained if patient agrees to participate in the study.
Consent will also be obtained from the primary service admitting the patient.
The Investigator (or IRB specified designee) is responsible for obtaining written consent from each 
participant or the participant's legally authorized representative in accordance with GCP guidelines 
using the approved informed consent form, before any study specific procedures (including 
screening procedures) are performed. The informed consent form acknowledges all information 
that must be given to the participant according to applicable GCP guidelines, including the purpose 
and nature of the study, the expected efficacy and possible side effects of the treatment(s), and 
specifying that refusal to participate will not influence further options for therapy. Any additional 
information that is applicable to the study must also be included. Additional national or 
institutionally mandated requirements for informed consent must also be adhered to. The 
participant should also be made aware that by signing the consent form, processing of sensitive 
clinical trial data and transfer to other countries for further processing is allowed.
The Investigator shall provide a copy of the signed consent form to the participant and the signed 
original shall be maintained in the Investigator File. A copy of the signed consent form must be 
filed in the participant file. At any stage, the participant may withdraw from the study and such a 
decision will not affect any further treatment options.
32 DRUGS OR DEVICES
Dexamethasone, metoclopramide, and octreotide are used singly or in different combination 
depending on the type of obstruction for the medical management of malignant bowel obstruction. 
All drugs are commercially available.
Drugs will not be provided for the study. Dexamethasone, metoclopramide, and octreotide will be 
paid for by the patient’s insurance carrier as part of the standard of care treatment.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 30 of 46
33 REFERENCES
1. Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: 
development of randomized trials for malignant bowel obstruction. J Pain Symptom 
Manage 2007;34(1 Suppl):S49-59 doi: 10.1016/j.jpainsymman.2007.04.011[published 
Online First: Epub Date]|.
2. Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced 
cancer patients: epidemiology, management, and factors influencing spontaneous 
resolution. Cancer Manag Res 2012;4:159-69 doi: 10.2147/CMAR.S29297[published 
Online First: Epub Date]|.
3. Ripamonti C, Easson A, Gerdes S. Bowel Obstruction. In: Cherny N, Fallon M, Kaasa S, 
Portenoy R, Currow D, eds. Oxford Textbook of Palliative Medicine. 5th ed. Oxford: 
Oxford University Press, 2015:9119-930.
4. Tradounsky G. Palliation of gastrointestinal obstruction. Can Fam Physician 2012;58(6):648-
52, e317-21 
5. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J 
Cancer 2008;44(8):1105-15 doi: 10.1016/j.ejca.2008.02.028[published Online First: Epub 
Date]|.
6. Ferguson HJ, Ferguson CI, Speakman J, Ismail T. Management of intestinal obstruction in 
advanced 
malignancy. 
Ann 
Med 
Surg 
(Lond) 
2015;4(3):264-70 
doi: 
10.1016/j.amsu.2015.07.018[published Online First: Epub Date]|.
7. Esha B, and Louis MWKS. Palliative enteroscopic stent placement for malignant mid-gut 
obstruction. Gastrointestinal Intervention 2014;3(1):30-34 
8. Mercadante S, Ferrera P, Villari P, Marrazzo A. Aggressive pharmacological treatment for 
reversing malignant bowel obstruction. J Pain Symptom Manage 2004;28(4):412-6 doi: 
10.1016/j.jpainsymman.2004.01.007[published Online First: Epub Date]|.
9. Prommer EE. Established and potential therapeutic applications of octreotide in palliative care. 
Supportive care in cancer : official journal of the Multinational Association of Supportive 
Care in Cancer 2008;16(10):1117-23 doi: 10.1007/s00520-007-0399-4[published Online 
First: Epub Date]|.
10. Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with 
advanced malignant disease. A clinical and pathological study. Lancet 1985;2(8462):990-
3 
11. Ventafridda V, Ripamonti C, Caraceni A, Spoldi E, Messina L, De Conno F. The management 
of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 
1990;76(4):389-93 
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 31 of 46
12. Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal 
obstruction in terminal cancer patients. J Pain Symptom Manage 1992;7(8):496-8 
13. Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. 
Critical 
reviews 
in 
oncology/hematology 
2012;83(3):388-92 
doi: 
10.1016/j.critrevonc.2011.12.006[published Online First: Epub Date]|.
14. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and 
hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant 
inoperable bowel obstruction. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer 2000;8(3):188-91 
15. Currow DC, Quinn S, Agar M, et al. Double-blind, placebo-controlled, randomized trial of 
octreotide in malignant bowel obstruction. J Pain Symptom Manage 2015;49(5):814-21 
doi: 10.1016/j.jpainsymman.2014.09.013[published Online First: Epub Date]|.
16. Berger J, Lester P, Rodrigues L. Medical Therapy of Malignant Bowel Obstruction With 
Octreotide, Dexamethasone, and Metoclopramide. Am J Hosp Palliat Care 
2016;33(4):407-10 doi: 10.1177/1049909115569047[published Online First: Epub Date]|.
17. Cannizzaro R, Bortoluzzi F, Valentini M, et al. Percutaneous endoscopic gastrostomy as a 
decompressive technique in bowel obstruction due to abdominal carcinomatosis. 
Endoscopy 1995;27(4):317-20 doi: 10.1055/s-2007-1005700[published Online First: Epub 
Date]|.
18. Kawata N, Kakushima N, Tanaka M, et al. Percutaneous endoscopic gastrostomy for 
decompression of malignant bowel obstruction. Dig Endosc 2014;26(2):208-13 doi: 
10.1111/den.12139[published Online First: Epub Date]|.
19. Pothuri B, Montemarano M, Gerardi M, et al. Percutaneous endoscopic gastrostomy tube 
placement in patients with malignant bowel obstruction due to ovarian carcinoma. 
Gynecologic oncology 2005;96(2):330-4 doi: 10.1016/j.ygyno.2004.09.058[published 
Online First: Epub Date]|.
20. Brooksbank MA, Game PA, Ashby MA. Palliative venting gastrostomy in malignant intestinal 
obstruction. Palliat Med 2002;16(6):520-6 doi: 10.1191/0269216302pm590oa[published 
Online First: Epub Date]|.
21. Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application 
for rapidly calculating Charlson comorbidity score. BMC cancer 2004;4:94 doi: 
10.1186/1471-2407-4-94[published Online First: Epub Date]|.
22. Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. 
In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents: Symposium Held at the 
New York Academy of Medicine. New York: Columbia University Press, 1949:191-205.
20. Clark K., Lam L., Currow D. Reducing gastric secretions–a role for histamine 2 antagonists or 
proton pump inhibitors in malignant bowel obstruction? 2009;17:1463–1468.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 32 of 46
34 APPENDICES/ SUPPLEMENTS
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 33 of 46
Appendix A: ELIGIBILITY VERIFICATION FORM: 
INCLUSION CRITERIA
Participant Name: ___________________________________________________
Medical Record No: __________________________________________________
Title: Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open 
Label, Phase-2 Study at an NCI Comprehensive Cancer.
INCLUSION CRITERIA
Yes
No
N/A
All answers must be “Yes” or “N/A” for participant enrollment.
Date
1.
Age ≥ 18 years of age.
2.
Diagnosis of partial bowel obstruction secondary to active or prior 
malignancy (primary or metastatic GI, GYN, and carcinomatosis) 
caused either by tumor itself or adhesions in the setting of active 
malignancy.
3.
Cross-sectional imaging performed within 24 hours of clinical 
symptoms of bowel obstruction (nausea, vomiting, and constipation ± 
abdominal pain) during hospital admission.
4.
Patient must have an inoperable MBO.
5.
Participant must understand the investigational nature of this study and 
sign an Independent Ethics Committee/Institutional Review Board 
approved written informed consent form prior to receiving any study 
related procedure.
Investigator Signature: ___________________________________
Date: ___________
Printed Name of Investigator: __________________________________________________
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 34 of 46
Appendix B: ELIGIBILITY VERIFICATION FORM:
EXCLUSION CRITERIA
Participant Name: ___________________________________________________
Medical Record No.: _________________________________________________
Title: Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open 
Label, Phase-2 Study at an NCI Comprehensive Cancer.
EXCLUSION CRITERIA
Yes
No
N/A
All answers must be “No” or “N/A” for participant enrollment.
Date
1.
Evidence of complete bowel obstruction by imaging.
2.
Bacteremia/septicemia with a documented positive blood culture: If a 
blood culture comes back positive after study enrollment, patient will 
be excluded.
3.
Patients already taking a steroid equivalent to 8 mg of dexamethasone 
per day for longer than 7 days prior to study enrollment.
4.
Patients undergoing bowel surgery or stent placement for bowel 
obstruction.
5.
Those patients with MBO in setting of incarcerated hernia.
6.
Known history of QT prolongation syndrome or if QTc is > 500 msec 
on baseline EKG within 2 weeks of enrollment.
7.
Lack of decision-making capacity/delirium.
8.
Pregnant or nursing female participants.
9.
Actively suicidal patients.
10. Acute cholecystitis.
11. History of seizure episode in the last 12 months or patient on a 
maintenance antiepileptic drug for seizure control.
12. Acute Pancreatitis.
13. Bowel perforation.
14. Patients taking antipsychotic drugs.
15. History of dystonia or tardive dyskinesia.
16. Patients with pheochromocytoma.
17. Elevated blood pressure 180 mmHg systolic or 120 mmHg diastolic.
18. Immunocompromised patients.
19. Patients with latent tuberculosis history.
20. Incarcerated patients.
21. Patient already enrolled in a clinical trial.
22. Unwilling or unable to follow protocol requirements.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 35 of 46
EXCLUSION CRITERIA
Yes
No
N/A
All answers must be “No” or “N/A” for participant enrollment.
Date
23. Any condition which in the Investigator’s opinion deems the participant 
an unsuitable candidate to receive study treatment.
Participant meets all entry criteria:
  Yes
  No
If “NO”, do not enroll participant in study.
Investigator Signature: ___________________________________
Date: __________
Printed Name of Investigator: _________________________________________________
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 36 of 46
Appendix C: Study Data Collection Sheet: Standardized Data Entry Protocol
1. Code 

This is the assigned patient number. 
2. Age at diagnosis

Enter age at diagnosis of bowel obstruction in years
3. Date of birth (mm/dd/yyyy)
4. Date of diagnosis of bowel obstruction
5. Patient characteristics
1. Gender
Select options from drop-down menu.
2. Ethnicity
Select options from drop-down menu.
3. Malignancy
Manually enter the type of malignancy
4. Cancer stage
Enter the stage at the time of diagnosis of bowel obstruction
5. Date of cancer diagnosis (mm/dd/yyyy): primary diagnosis
6. BMI
Enter the BMI on admission at the time of diagnosis of bowel obstruction
7. BMI Class
Select options from drop-down menu (where BMI = kilograms/ meters2).
8. Smoking
Select options from drop-down menu.
9. Alcohol
Select options from drop-down menu.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 37 of 46
10. Prior use of steroids (include use for up to 1 month prior to hospitalization)
a.
If yes, manually enter the details (name and dosing schedule)
11. Comorbidities
a.
Cardiovascular: Select options from drop-down menu.
b. Pulmonary: Select options from drop-down menu.
c.
Renal: Select options from drop-down menu.
d. Neurological: Select options from drop-down menu.
e.
Endocrine: Select options from drop-down menu.
f.
Infectious Disease: Select options from drop-down menu.
g. Hematologic/Oncologic: Select options from drop-down menu.
h. Liver/Gastrointestinal: Select options from drop-down menu.
12. Comorbidity index score [21]: Calculate the score according to the table:
Comorbidity
Score
CAD
1
CHF
1
PAD
1
COPD
1
CVA with no deficits
1
Dementia
1
PUD
1
Mild liver disease
1
DM without end-organ damage
1
DM with end-organ damage
2
Leukemia/Lymphoma
2
Moderate-severe renal disease
2
Hemiplegia
2
Moderate-severe liver disease
3
Metastatic solid tumor
6
AIDS (not just HIV)
6
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 38 of 46
13. Personal history of bowel obstruction
Select options from drop-down menu.
14. History of bowel surgery
Select options from drop-down menu.
15. Partial vs complete obstruction
Enter data based on the imaging description
16. Location
Enter data based on the imaging description
17. Symptoms on admission
a.
Nausea
b. Vomiting
c.
Abdominal pain
d. Constipation
e.
Others: Manually enter other symptoms present on admission
18. Imaging type
Select options from drop-down menu.
19. Karnofsky score on admission
Enter Karnofsky score at admission
20. Drug Regimen
a.
Octreotide
b. Dexamethasone
c.
Metoclopramide
21. Inpatient Anti-emetics Drug Names
22. Inpatient Pain Regimen Drug Names
23. NG tube
a.
Inserted
b. If yes, enter the day of bowel obstruction when it was inserted
c.
Average output in mL per day
d. Total number of NG-inserted-days
e.
Removed before discharge
f.
If yes, enter the day of bowel obstruction when it was removed
24. G-tube
a.
Present prior to study
b. Inserted during study
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 39 of 46
c.
If yes, enter the date when it was inserted
d. Average output in mL per day
25. De-obstruction 
a.
Yes
i. Time to de-obstruction in days 
ii. Follow up number of days post de-obstruction
iii. Discharged post de-obstruction
iv. Completed outpatient treatment regimen
b. No
i. Venting PEG Placed
26. Adverse effects during trial
27. 30-day Follow Up in clinic
28. Phone Call Follow Up
a.
3 months
b. 6 months
29. Disposition
a.
Home
b. Hospice
c.
LTC (long-term care) or SAR (sub-acute rehabilitation)
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 40 of 46
Appendix D: Karnofsky Performance Scale
Karnofsky Performance Scale [22]
Percent
Description
100
Normal, no complaints, no evidence of disease.
90
Able to carry on normal activity, minor signs, or symptoms of disease.
80
Normal activity with effort, some signs, or symptoms of disease.
70
Cares for self. Unable to carry on normal activity or to do active work.
60
Requires occasional assistance but is able to care for most of his needs.
50
Requires considerable assistance and frequent medical care.
40
Disabled, requires special care and assistance.
30
Severely disabled, hospitalization is indicated although death not imminent.
20
Hospitalization necessary, very sick, active supportive treatment necessary.
10
Moribund, fatal processes progressing rapidly.
0
Dead.
Karnofsky, D.A., and Burchenal, J.H. (1949). The Clinical Evaluation of Chemotherapeutic 
Agents in Cancer. In Evaluation of Chemotherapeutic Agents: Symposium Held at the New York 
Academy of Medicine, C.M. MacLeod, ed. (New York, Columbia University Press), pp. 191-205.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 41 of 46
Appendix E: Assessment Sheet 
I-70418 Assessment Sheet
/
PI: Dr. Amy Case 
Directions for Nursing Staff:  Please complete once during your shift and file in designated 
folder.
Date:____________________
MRN: _________________________________
Time:______________________
Nurse Performing Assessment:______________
CAM-S Short Form Scoring Worksheet:  Circle appropriate score for each question.
Feature
Severity Score
1. Acute Onset and Fluctuating Course
Is there evidence of an acute change in mental status from 
patient’s baseline? 
OR
Did the (abnormal) behavior fluctuate during the day, that is – 
tend to come and go, or increase and decrease in severity? 
Either present: 
No:                       
Yes                      
0
1
2. Inattention
Did the patient have difficulty focusing attention, for example, 
being easily distractible or having difficulty keeping track of 
what was being said? 
No:                      
Yes (mild):           
Yes (marked):      
0
1
2
3. Disorganized Thinking
Was the patient’s thinking disorganized and incoherent, such as 
rambling or irrelevant conversation, unclear or illogical flow of 
ideas, or unpredictable switching from subject to subject?
No:                      
Yes (mild):           
Yes (marked):     
0
1
2
4. Altered Level of Consciousness
Overall, how would you rate the patient’s level of 
consciousness?

Alert (normal 

Vigilant (hyperalert)

Lethargic (drowsy, easily aroused)

Stupor (difficult to arouse)
No:                       
Mild (vigilant or 
lethargic):             
Marked: (stupor or 
coma):                   
0
1
2
Severity Score Total*: (Add the score in rows 1-4)
*Notify provider if total score equals 2 or greater. 
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 42 of 46
Condensed Memorial Symptom Assessment Scale (cMSAS):  Ask patient “How much does 
this symptom bother you today?”  If symptom present, circle patient’s score.  
Symptom
Present
Not at all
A little bit
Somewhat
Quite a bit
Very 
much
Abdominal pain 
due to 
cancer/obstructi
on
Y        N
0
1
2
3
4
Constipation
Y        N
0
1
2
3
4
Nausea
Y        N
0
1
2
3
4
Vomiting
Y        N
0
1
2
3
4
Has patient had a bowel movement 
in last 24 hours?
Y
N
Is patient able to tolerate oral 
intake?
Y
N
For questions, please contact Sarah Chatley, Research Coordinator, at x. 5055 or 
Sarah.Chatley@RoswellPark.org.
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 43 of 46
Appendix F: Hypoglycemia Protocol
The following (modified) Hypoglycemia Protocol is taken from the Roswell Park Cancer Institute 
CLINICAL GUIDELINES FOR GLUCOSE MANAGEMENT IN ADULT ACUTE CARE 
INPATIENTS (Section 6: Hypoglycemia Treatment):
Hypoglycemia Protocol for Patients NOT on an Insulin Infusion
Blood glucose > 40 mg/ dL but < 60 mg/ dL:
Nursing Orders:
1
If patient can take PO: administer 15 grams of carbohydrate (4 oz of fruit juice-orange or 
apple, or regular soda)
2
If patient unable to take PO: administer 12.5 grams of dextrose 50% IV (25 mL) or 1 mg 
of glucagon IM
3
Check blood glucose every 15 minutes and repeat above treatment until blood glucose is 
≥ 80 mg/ dL
4
Notify MD if blood glucose is ≤ 70mg/ dL
Blood glucose < 40 mg/ dL:
Nursing Orders:
1
If patient can take PO: administer 30 grams of carbohydrate (8 oz of fruit juice-orange or 
apple, or regular soda)
2
If patient unable to take PO: administer 25 grams of dextrose 50% IV (50 mL) or 1 mg of 
glucagon IM
3
Check blood glucose every 15 minutes and repeat above treatment until blood glucose is 
≥ 80 mg/ dL
4
Notify MD if blood glucose is ≤ 40mg/ dL
Hypoglycemic signs and symptoms:
1
Trembling or Shaking, Cold Clammy Skin
2
Diaphoresis, Palpitations, Tachycardia
3
Hunger, Nausea, Headache, Tiredness, Weakness
4
Sudden Visual Changes, Paresthesia around Lips & Tongue
5
Slurred Speech, Lack of Coordination
6
Mental Dullness, Inability to process information
7
Behavior Changes, Confusion, Hallucinations
8
Amnesia, Seizures, Convulsions, Coma
APPROVED RPCI IRB
10/21/2021

Roswell Park Protocol No.: I 74018
10/18/21
Page 44 of 46
Appendix G: Schedule of Procedures and Observations
Time Point
Pre-
treatment 
Screening1
Day 1-7
Discharge/End of 
Treatment (±3 days)
Outpatient 
Treatment 2
Post-Treatment Follow-
Up 30 days after study 
drugs (±3 days)3
Long Term Follow-Up- 3 
Mos. And 6 Mos. Post-
discharge7
Clinical Procedures
Medical/Surgical History
X
Co-Morbidity Index Score
X
Physical Examination4
X
Vital Signs5
X
Karnofsky Score
X
Concomitant Medications6
X6
X
X
X
Adverse Events7
X
X
X
X
X
Smoking and Alcohol 
History
X
cMSAS8
X
CAMS-S9 (Delirium Screen 
while on Decadron)
X
De-obstruction 
Assessment10
X
X
X
Laboratory Procedures
Chemistry   
X
X
BMP
X
X

Roswell Park Protocol No.: I 74018
10/18/21
Page 45 of 46
Time Point
Pre-
treatment 
Screening1
Day 1-7
Discharge/End of 
Treatment (±3 days)
Outpatient 
Treatment 2
Post-Treatment Follow-
Up 30 days after study 
drugs (±3 days)3
Long Term Follow-Up- 3 
Mos. And 6 Mos. Post-
discharge7
Pregnancy Test (Urine or 
Serum) in women of child-
bearing potential
X
Imaging Procedures
EKG (within 2 weeks of 
study registration)11
X
X
X
Cross sectional imaging12
X
Surgical Consult (if 
needed)13
Day 7 
only
Treatment Regimen/Drug 
Administration
Octreotide14
X
X
Dexamethasone15
X
X
X (Change to 
Oral)
Metoclopramide15
X
X
X (Change to 
Oral)
1.
Performed with 48 hours to treatment start (ideally 24 hours).
2.
If de-obstruction occurs in 7 days or less, patient continues regimen until the 10-day treatment period is complete.  If the patient de-obstructs the drug 
regimen will be transitioned to oral for metoclopramide and dexamethasone, and IV or sub-cutaneous for octreotide is discontinued.  If patient 
discharged home the CRC will contact the patient daily for 3 days following discharge to monitor adverse events and treatment administration 
(including missed doses).
3.
Participants will be followed for 30 days ±3 days after last dose of study drug, telephone contact is acceptable.
4.
PE must include physical symptoms of MBO.
5.
Vital signs (temperature, heart rate, respiratory rate, and blood pressure), body weight, and height.
6.
Medications ongoing, or discontinued, with 1 week prior to first dose of study drug.  Steroid use for up to 1 month prior to hospitalization.
7.
After patient discharge AE and con med assessments can be collected by phone.  At Post-Treatment Follow-Up, CRC will assess regularity of bowel 
movements and toleration of oral intake.
8.
Condensed Memorial Symptom Assessment Scales assessed by inpatient nurses using study form (Appendix E).

Roswell Park Protocol No.: I 74018
10/18/21
Page 46 of 46
9.
Confusion Assessment Method-Short Form assessed by inpatient nurses using study form (Appendix E). 
10. De-obstruction defined as effective introduction of oral intake as per study.
11. EKGs will be performed prior to discharge (±3 days) or at the time of treatment discontinuation (±3 days).
12. Performed within 24 hours of clinical symptoms of bowel obstruction (nausea, vomiting, and constipation ± abdominal pain) during hospital admission.
13. At the discretion of the clinician, surgical consult can be obtained for possible venting G-tube placement if de obstruction does not occur within 7 days 
of treatment initiation.